Mauna Kea Technologies SA Class O ALMKT
EURONEXT · France · Health Technology
€0.14000.00 (0.00%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
PARIS, September 07, 2026--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):
PARIS & BOSTON, August 26, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication of a landmark independent systematic review and meta-analysis of probe-based confocal laser endomicroscopy (pCLE) in upper gastrointestinal cancer, conducted and funded by Korea's national health technology assessment agency.
PARIS & BOSTON, July 28, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that two new peer-reviewed studies published across leading gastroenterology journals reinforce the growing body of evidence supporting needle-based confocal laser endomicroscopy (nCLE) for the diagnosis of pancreatic cystic lesions (PCLs).
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.